All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-6249
Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs
Documents
34
Comments
386
Description
Open
Key Dates
Comment Period OpensJun 3, 2026
Documents
| Type | Title | Status |
|---|---|---|
Supporting Material |
Comment Statistics
Total Comments
386
Keywords
CVM
Citizen Petition
Pharmaceutical Safety Oversight Council
Request that the FDA, acting through
its Center for Veterinary Medicine (CVM),
exercise its post-approval oversight authority
to impose enforceable safe-use conditions for
Librela (bedinvetmab injection) (NADA 141-562),
Data from Regulations.gov